Recent Updates
Recently added Catalysts
VIR Positive Sentiment

Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data

Sunday, November 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Vir Biotechnology reported expanded Phase 2 SOLSTICE trial data for elebsiran and tobevibart in chronic hepatitis delta. The new analyses, presented at the AASLD The Liver Meeting 2026, indicate significant and sustained viral suppression over time. This promising data supports the potential of these treatments in managing chronic hepatitis delta.

Market Sentiment Analysis

POSITIVE FACTORS

  • Expanded data shows deep viral suppression.
  • New analyses presented at a major liver disease meeting.
  • Monthly administration of drugs shows promise.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
9.5%
average across 6 past catalysts
Cash runway
~13 mo
Medium dilution risk
Lead asset
Tobevibart
Phase 3 · Viral Hepatitis

Full Press Release Details

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced new, expanded data from the Phase 2 SOLSTICE trial evaluating monthly subcutaneous administration of elebsiran and tobevibart in adults with chronic hepatitis delta (CHD). These data include new analyses presented in oral sessions at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026, in Denver, Colorado. “We are seeing rapid viral suppression that deepens over time, alon

Frequently Asked Questions

What is the SOLSTICE trial?

The SOLSTICE trial evaluates elebsiran and tobevibart in chronic hepatitis delta.

What were the results of the Phase 2 trial?

The trial showed deep and sustained viral suppression over time.

Where were the new data presented?

The data were presented at the AASLD The Liver Meeting 2026.

What is the significance of the new data?

The data support the potential effectiveness of the treatments.

ShareAdd on Google
Tags: VIR Vir Biotechnology elebsiran tobevibart chronic hepatitis delta SOLSTICE trial
Last updated: Nov 8, 2026

Biotech snapshot

Cash runway
$455M liquidity · $35M/mo burn
~13 mo
Medium dilution risk
Lead asset
TobevibartPhase 3
Viral Hepatitis →

Catalyst track record

+85%
best trade around VIR's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for VIR.

See every catalyst's timing & PoA →